PPT-Antibodies, BiTEs , and CARs: the new ABC’s of Myeloma Therapy

June 6 2019 Adam D Cohen MD Director Myeloma Immunotherapy Assistant Professor Medicine Abramson Cancer Center University of Pennsylvania Outline Background Antibodies and antibodydrug conjugates. These b nd partners also known as tar et molecules r anti ens are often parts of proteins which are the most important components of livin cells Antibodies are therefore ideal search en ines for detectin minuscule amounts of a art cular tar et molec 6.5 Antibodies . Learning outcomes. Student should be able to understand the following:. Antibody structure and the formation of an antigen-antibody complex. The use of monoclonal antibodies in enabling the targeting of specific substances and cells.. Ruben Niesvizky. Myeloma Center. Myelomacenter.org. run9001@med.cornell.edu. Multiple Myeloma: Natural History of Disease. Durie B; International Myeloma Foundation. . Concise review of the disease and treatment options: multiple myeloma. 2011/2012 edition;. Rochester, Minnesota. Jacksonville, Florida. Multiple . Myeloma. Monitoring and Therapy. Angela Dispenzieri, M.D.. IMF Patient Workshop . November 4, 2014. . Mayo Clinic College of Medicine . Mayo Clinic Comprehensive Cancer Center. Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. Reported by . Ganesh . M.Sc.D. . endo. student. What is immunoglobulin ?. Immunoglobulin's . are glycoprotein molecules that are produced by plasma cells in response to an immunogen and which function as antibodies. The . new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. mAb. production……... Prsented. by…... Abhilasha. . tiwari. Ankita. . Dwivedi. Arijit. . Biswas. Jasmine . Kaur. HYBRIDOMA TECHNOLOGY. A . hybridoma. is a hybrid cell obtained by fusion of B lymphocyte with usually a tumor cell of antibody forming system or b . Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Miss Georgia Stewart . Sheffield Myeloma Research Team. Department of Oncology and Metabolism. Faculty of Medicine Dentistry and Health . University of Sheffield, UK. Most Viruses have a preferential tropism for tumour cells. Myeloma Symposium 9/29/2018. Aric Hall, MD – Assistant Professor – UW School of Medicine & Public Health. Disclosures. I have no significant conflicts of interest to disclose. . I have no financial relationship with any institution profiting from pharmaceutical sales, diagnostic testing, or any type of medical technology. . Learning outcomes. Student should be able to understand the following:. Antibody structure and the formation of an antigen-antibody complex. The use of monoclonal antibodies in enabling the targeting of specific substances and cells.. Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma.